| http://www.w3.org/ns/prov#value | - Merck hasn't said why the FDA rejected MK-0524A. it is possible that the agency may require all companies to run a study showing that a cholesterol-lowering drug reduces the rate of cardiac events, such as heart attacks and other complications, before it will approve the drug for less needy patients.
|
